Abstract
The use of combination therapies*, as well as FDA-approved drugs for off-label indications, to treat advanced cancer, is widespread. While much is known about their clinical effectiveness, there exists no examination of the relative cost of novel multidrug combinations vs. traditional available therapy options, or study as to how knowledge about comparative therapy costs at the point-of-care can be leveraged by doctors, health systems, and payers. We found that:
combination multidrug cancer regimens may be less costly than monotherapies or other standard options;
novel, multidrug combinations are often better financial values than monotherapies or other standard options;
having treatment cost and value data, at the point of care, enables the prompt selection of more cost-effective medications and the avoidance of expensive low-value therapies that are financially wasteful.
We conclude that the effectiveness of value-based purchasing initiatives may be amplified if physicians and payers use comparative treatment cost/value data to enhance their cancer drug-selection decision making.
* Including combinations of immunotherapies, chemotherapies, targeted drugs with distinct mechanisms of action, etc.
Study Highlights What Is The Current Knowledge On The Topic?
☑ The effectiveness of molecularly targeted multidrug therapies used to treat advanced cancer is well established; 1-4 that few clinicians are aware of the cost of the medications they prescribe, or which are more cost-effective, deliver a better return-on-investment or represent a financial value; 8 and, that it is intuitive to believe that a combination of multiple high-cost medications is more expensive than a single-drug or other standard therapy options.
What Question Did This Study Address?
☑ Although studies on the clinical impact of multidrug cancer treatments abound, 1-4 there are no examinations of the relative cost or value of combination therapies vs. that of traditional monotherapies, or how knowledge of how this data can be used in practice. A systematic method to calculate, evaluate and compare the relative cost of mono-therapies, 2- and 3-drug combination cancer therapy options is presented for use by physicians, health systems and payers to better manage their oncology specialty pharmacy spend and drive better medical outcomes. 3
What Does This Study Add To Our Knowledge?
☑ We show that multidrug cancer therapies are not necessarily more costly than single-drug or other standard therapy options; and that furnishing physicians and payers with comparative treatment cost and value data to augment their complex medication selection decision making enables them to identify drugs that are a value, avoid those that are wasteful, and create better targeted novel combination cancer therapies that represent a value, which incorporates both clinical and financial aspects.
How Might This Change Combination Therapy Drug Selection Or Value-Based Oncology Management?
☑ Clinicians have the tools, information, and data with which to confidently prescribe novel drug combinations that customize molecular targeting, and lower treatment costs. Payers now have a framework within which to drive value-based purchasing to gain control of their oncology specialty drug risk. Patients will benefit from more personalized, efficient and effective therapies and less financial toxicity (i.e., distress).
Competing Interest Statement
The Research Consortium serves as a healthcare industry advisor and payer product development consultant to CureMatch, Inc. which provided partial funding for this research.
Funding Statement
No funding source had any role in any aspect of this analysis and the existence of any relationship does not constitute a conflict of interest, or otherwise bias the impartiality, or compromise the integrity, of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version of the manuscript has been updated to increase the "N" from N=5 to N=10 (Case Studies)
Data Availability
All data produced in the present study are available upon reasonable request to the authors
